Overview
Title
To amend title XVIII of the Social Security Act to clarify congressional intent and preserve patient access to home infusion therapy under the Medicare program, and for other purposes.
ELI5 AI
The bill H.R. 2172 is about making sure people can get medicine at home through Medicare and letting nurses help with plans for this at-home care, but some parts might make it hard to keep track of costs and how the care is done.
Summary AI
The bill H.R. 2172 aims to amend the Social Security Act to ensure that patients can continue to access home infusion therapy through Medicare. It includes provisions to recognize and reimburse pharmacy services as part of home infusion therapy, allows nurse practitioners and physician assistants to establish and review home infusion plans of care, and specifies payment rules for different home infusion scenarios. The bill also clarifies billing for non-pump infusion drugs and modifies payment for certain home infusion supplies. These changes are set to take effect on January 1, 2026.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
General Summary
House Bill 2172, introduced in the 119th Congress, aims to amend the Social Security Act to ensure patients maintain access to home infusion therapy covered by Medicare. Specifically, it seeks to address the challenges of providing home infusion therapy by including pharmacy services, adjusting payment methods, and allowing broader provider participation in care planning. The bill is set to be enforced starting January 1, 2026, and covers various changes to the existing legislative framework to enhance efficiency and accessibility.
Significant Issues
Several issues arise from the proposed amendments:
Inclusion of Pharmacy Services: The addition of pharmacy services in home infusion therapy might increase costs. The bill lacks a detailed cost-benefit analysis to justify these expenses.
Payment without Physical Presence: There are provisions for payments when qualified suppliers are not physically present, which could open avenues for overbilling and reduce direct oversight.
Broadened Provider Roles: The inclusion of nurse practitioners and physician assistants in establishing care plans could raise concerns over the adequacy of oversight and training.
Ambiguity and Complexity: Terms like "specified non-pump drug or biological" depend on external classifications that might change over time, potentially complicating implementation.
Delayed Implementation: The effective date of January 1, 2026, could result in a delay in addressing current challenges in the home infusion sector.
Potential Impact on the Public
For the general public, this bill could improve access to vital health services by expanding who can provide home infusion therapy and how these services are managed. Patients who rely on home-based treatments may find these services to be more comprehensive and accessible. However, the complexity of the bill can make it challenging for laypersons to understand how these changes might directly affect their healthcare options.
Impact on Stakeholders
Patients: Patients may benefit from improved access and perhaps more timely services. The facility of including nurse practitioners and physician assistants in care planning might make it easier for them to receive ongoing care without unnecessary delays.
Healthcare Providers: While expanding the roles of nurse practitioners and physician assistants could help with workforce shortages, it might also pose challenges if adequate training and oversight are not ensured.
Medicare and Regulatory Bodies: The inclusion of pharmacy services and the payment clauses might strain resources unless carefully managed through oversight to prevent potential overbilling and misuse.
Pharmaceutical and Medical Supply Companies: The bill offers new business avenues with home infusion drugs, especially those not requiring pumps. However, the lack of immediate implementation might mean a delayed market entry.
In sum, while House Bill 2172 makes strides towards meeting contemporary healthcare needs, it also necessitates careful consideration and additional clarification to ensure effective implementation and to address the latent concerns surrounding costs and proper oversight.
Issues
The amendment to Section 1861(iii)(2) of the Social Security Act includes pharmacy services in home infusion therapy, which could potentially increase costs without any cost-benefit analysis to justify this inclusion. [Section 2]
The amendment in Section 1834(u)(1)(A), clause (ii) of the Social Security Act permits payment for each day a drug is administered even without the physical presence of a qualified supplier, potentially leading to overbilling without direct oversight. [Section 2]
Allowing nurse practitioners and physician assistants to establish and review home infusion plans might raise scope of practice concerns, as mentioned in Section 1861(iii)(1)(B), especially if there is inadequate oversight or training, which is not addressed in the bill. [Section 2]
The transitional rule in clause (iii)(B)(II) specifying a single payment amount for 5 hours of therapy without a clear rationale might not align with actual therapy needs, leading to inefficiencies or misaligned incentives. [Section 2]
Ambiguity in the definition of 'specified non-pump drug or biological' as it relies on categories determined by the United States Pharmacopeia, which may change over time. This could affect clarity and implementation. [Section 3]
The potential exclusion of certain payments for 'applicable items and services' associated with home infusion therapy in Section 1834(a) might be complex and difficult for laypersons to understand, raising the risk of provider confusion and impacting patient access. [Section 4]
The special rule in clause (iv) offering 50% payment for services without the supplier's physical presence may encourage minimal supervision, risking patient safety or care quality. [Section 2]
The future effective date of amendments (January 1, 2026) may delay responses to current issues in the home infusion therapy market, leading to inefficient or wasteful spending in the interim period. [Sections 2, 3, and 4]
Language complexity throughout the bill may compromise its transparency and accountability to the general public, making it difficult for stakeholders to understand the amendments. [Sections 2, 3, and 4]
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The first section of this bill states that the act will be known as the "Preserving Patient Access to Home Infusion Act."
2. Preservation of patient access to home infusion therapy under Medicare program Read Opens in new tab
Summary AI
The section updates the Social Security Act to include pharmacy services in home infusion therapy under Medicare, provides new rules for payment calculations when therapy suppliers are not present, allows nurse practitioners and physician assistants to take a more active role in care planning, and sets the changes to take effect starting January 1, 2026.
3. Access to home infusion for non-pump drugs and biologicals Read Opens in new tab
Summary AI
The section modifies the definition of home infusion drugs in the Social Security Act to include certain drugs or biologicals that are not administered through a pump but still qualify for home infusion, specifically those that are antibacterial, antifungal, or antiviral. It also clarifies billing procedures for suppliers of these drugs when a pump is not involved, with changes effective starting January 1, 2026.
4. Modification of payment for home infusion supplies Read Opens in new tab
Summary AI
The amended section of the Social Security Act specifies that starting January 1, 2026, certain items and supplies used with home infusion therapy will not receive separate payments if they are used on the same day as the therapy itself. This includes supplies like tubing, catheters, and needles identified by specific HCPCS codes.